title: The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.
abstract: BACKGROUND
  Inadequate blood pressure (BP) control remains a serious concern worldwide. Recent evidence suggests that the combination of a calcium channel blocker (CCB) with an angiotensin-converting enzyme inhibitor (ACEi) in patients with essential hypertension provides effective BP control with decreased adverse cardiac and renal events.
  
  
  OBJECTIVE
  This study was designed to quantitatively evaluate the efficacy and tolerability of a fixed dose combination of perindopril and amlodipine in the Kingdom of Saudi Arabia on a population of patients with essential hypertension, as well as to identify the predictors of BP control in this population.
  
  
  METHODS
  This was an observational, multicenter, open-label cohort study of patients with essential hypertension with or without diabetes mellitus, treated with a fixed dose combination of perindopril and amlodipine. Patients were followed up in four-week intervals for a total of 12 weeks. They were initially started on the lowest dose of the ACEi/CCB combination and up-titrated at each follow-up according to their response to treatment. The primary end-point of the study was the percentage of patients with controlled BP at study termination (week 12).
  
  
  RESULTS
  A total of 1996 patients completed the study. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) control was observed in 93.3% of patients at week 12. As for the predictors of BP control, it was found that female gender was associated with more BP control [odds ratio (OR) = 1.76, 95% CI: 1.14-2.70, p value = 0.01], whereas older age was associated with less BP control (OR = 0.98, 95% CI: 0.96-1.00, p value = 0.02). Similarly, having type I and type II diabetes mellitus was also associated with less BP control (OR = 0.19, 95% CI: 0.08-0.45, p < 0.0001 and OR = 0.33, 95% CI: 0.22-0.48, p < 0.0001, respectively). In a qualitative assessment, both investigators and patients perceived efficacy and tolerability of perindopril/amlodipine to be excellent.
  
  
  CONCLUSIONS
  We found that a fixed combination of perindopril/amlodipine is effective in controlling BP in patients with essential hypertension, with older age, male gender, and diabetes mellitus being independent risk factors for less BP control.
authors.affiliation: Faculty of Medicine, Ain Shams University Cardiology, Cairo, Egypt.
authors.forename: Ayman
authors.initials: A
authors.lastname: Abdelhady
authors.affiliation: Royal College of Physician of Edinburgh, Scotland, UK.
authors.forename: Said
authors.initials: S
authors.lastname: Khader
authors.affiliation: Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
authors.forename: Samy
authors.initials: S
authors.lastname: Sinnuqrut
authors.affiliation: Faculty of Pharmacy, University of Science and Technology, Irbid, Jordan. abdullah.al-bow@servier.com.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Albow
mesh_terms: D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D015331:Cohort Studies; D004338:Drug Combinations; D000075222:Essential Hypertension; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage*; D012529:Saudi Arabia / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004338:Drug Combinations; C542336:amlodipine, perindopril drug combination; D017311:Amlodipine; D020913:Perindopril
references.citation: Herz. 2014 Dec;39(8):952-6
references.pmid: 25384853
references.citation: J Womens Health (Larchmt). 2005 Jun;14(5):418-23
references.pmid: 15989414
references.citation: Pan Afr Med J. 2014 Aug 05;18:278
references.pmid: 25489372
references.citation: Semergen. 2015 Jan-Feb;41(1):13-23
references.pmid: 24703582
references.citation: Eur Heart J. 2013 Jul;34(28):2159-219
references.pmid: 23771844
references.citation: Hypertension. 2000 Oct;36(4):594-9
references.pmid: 11040241
references.citation: Lancet. 2011 Feb 12;377(9765):568-77
references.pmid: 21295844
references.citation: Ann Saudi Med. 2008 Sep-Oct;28(5):346-51
references.pmid: 18779643
references.citation: Diabetes Metab Syndr. 2013 Apr-Jun;7(2):83-6
references.pmid: 23680246
references.citation: BMJ. 2008 May 17;336(7653):1121-3
references.pmid: 18480116
references.citation: Hypertension. 2008 Apr;51(4):1149-55
references.pmid: 18259013
references.citation: J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404
references.pmid: 12461301
references.citation: Circulation. 2007 May 29;115(21):2761-88
references.pmid: 17502569
references.citation: J Am Soc Hypertens. 2013 Mar-Apr;7(2):163-9
references.pmid: 23428412
references.citation: Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H466-74
references.pmid: 18567715
references.citation: Am J Med. 2009 Mar;122(3):290-300
references.pmid: 19272490
references.citation: J Hum Hypertens. 2015 May;29(5):283-91
references.pmid: 25355012
references.citation: Clin Drug Investig. 2012 Sep 1;32(9):603-12
references.pmid: 22877321
references.citation: Int J Hypertens. 2011;2011:174135
references.pmid: 21912737
references.citation: Ethn Dis. 2009 Spring;19(2):148-53
references.pmid: 19537225
references.citation: J Hypertens. 2014 Dec;32(12):2401-10; discussion 2410
references.pmid: 25198422
references.citation: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD006742
references.pmid: 22895954
references.citation: Nefrologia. 2011;31(3):313-21
references.pmid: 21629337
references.citation: JAMA. 2014 Feb 5;311(5):507-20
references.pmid: 24352797
references.citation: Curr Med Chem. 2015;22(3):305-42
references.pmid: 25386825
references.citation: Am J Cardiovasc Drugs. 2009;9(3):135-42
references.pmid: 19463019
references.citation: J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50
references.pmid: 20374950
references.citation: Am J Hypertens. 2004 Oct;17(10):915-20
references.pmid: 15485754
references.citation: Diabetes Care. 2013 Mar;36(3):591-7
references.pmid: 23150284
references.citation: Int J Hypertens. 2014;2014:564679
references.pmid: 25170423
references.citation: JAMA. 2009 Jul 22;302(4):401-11
references.pmid: 19622819
references.citation: N Engl J Med. 2008 Dec 4;359(23):2417-28
references.pmid: 19052124